Enfuvirtide

FDA-approved HIV fusion inhibitorEstablished

Also known as: Fuzeon, T-20, DP-178

Enfuvirtide (also called Fuzeon or T-20) is an FDA-approved HIV fusion inhibitor. Enfuvirtide is a thirty-six-amino-acid peptide derived from the HR2 region of the HIV-1 envelope glycoprotein gp41. During viral entry gp41 must fold so that its HR1 and HR2 regions pack into a six-helix bundle, and it is the energy of that collapse that pulls the viral and cell membranes together.

Calculate Dose

For research use only.

Key Facts

CAS
159519-65-0
Molecular Weight (MW)
4491.4 g/mol
Half-life
About 3.8 hours after a 90 mg subcutaneous dose
FDA status
Approved
Evidence level
FDA Approved
Human dose established
Yes
Administration Route
Subcutaneous
Frequency
Twice daily
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
HIV-1 gp41

Research summary

FDA-approved HIV-1 fusion inhibitor (Fuzeon) for treatment-experienced patients. 90 mg subcutaneous twice daily with other antiretrovirals.

Research evidence

  • Regulatory review (FDA label)2 reviewed sources
  • Controlled human trials1 reviewed source
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Enfuvirtide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Enfuvirtide dosage evidence

Enfuvirtide has an FDA-approved human dosage, as Fuzeon, for treatment-experienced people with HIV-1 who still have detectable virus despite ongoing antiretroviral therapy, always combined with other antiretrovirals. The label's adult dose is 90 mg (1 mL) injected under the skin twice daily; children weighing at least 11 kg receive 2 mg/kg twice daily, up to 90 mg twice daily.

FDA Approved
Dosage evidence summary for Enfuvirtide
Human dosing establishedYes
RouteSubcutaneous
FrequencyTwice daily
Duration studiedLong-term, as part of combination antiretroviral therapy
Half-lifeAbout 3.8 hours after a 90 mg subcutaneous dose
Evidence levelFDA Approved
Last reviewed2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Enfuvirtide, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
FDA label — Fuzeon, adultsFDA-approved label · FDA prescribing informationTreatment-experienced adults with HIV-1 replication despite ongoing antiretroviral therapy90 mg (1 mL)Subcutaneous (upper arm, front of thigh or abdomen)Twice dailyOngoing, with other antiretroviralsTreatment of HIV-1 infectionFUZEON (enfuvirtide) for injection — FDA prescribing information, revised 8/2019 (Drugs@FDA)
FDA label — Fuzeon, childrenFDA-approved label · FDA prescribing informationTreatment-experienced children with HIV-1 weighing at least 11 kg2 mg/kg, up to 90 mg; the label's weight table runs from 27 mg (11–15.5 kg) to 90 mg (42.6 kg and over)SubcutaneousTwice dailyOngoing, with weight checked and the dose adjusted periodicallyTreatment of HIV-1 infectionFUZEON (enfuvirtide) for injection — FDA prescribing information, revised 8/2019 (Drugs@FDA)
TORO 1 — phase 3, NEJM 2003Clinical trial · Randomised, open-label phase 3 trialAdults with multidrug-resistant HIV-1 after at least six months of three drug classes (501 randomised)Enfuvirtide with an optimised background regimen of three to five antiretrovirals, or the background regimen alone (dose not stated in the indexed abstract)Not stated in the indexed abstractNot stated in the indexed abstract24 weeks to the primary endpointMean viral load fell by 1.696 log10 copies/mL with enfuvirtide versus 0.764 with the background regimen alone; injection-site reactions in 98% of patients and more pneumonia with enfuvirtideEnfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003.

Where sources disagree

  • Fuzeon has no current label on DailyMed, and Drugs@FDA lists the product as discontinued; the dosing above is from its last FDA prescribing information (August 2019) on Drugs@FDA.
  • The label reports local injection-site reactions in 98% of trial participants and an increased rate of bacterial pneumonia compared with the control arm; it also warns about hypersensitivity reactions and post-injection bleeding.
  • The label says each single-dose vial must be reconstituted only with the 1 mL of Sterile Water for Injection provided in its kit.
Enfuvirtide dosage in published studies and labels →

Handling & administration

Reconstitution Guide
Reconstitute 90 mg vial with 1.1 mL sterile water for injection
Injection Sites
AbdomenArmThigh
Concentration Example
90 mg vial + 1.1 mL → 90 mg/mL
Timing Notes
Inject subcutaneously in upper arm, anterior thigh, or abdomen, rotating injection sites
Expected Onset
Viral load reduction typically seen within 2-4 weeks

Sequence & molecular data

Sequence and molecular data for Enfuvirtide
Molecular formulaC204H301N51O64
Molecular weight4491.4 g/mol
CAS number159519-65-0
Half-life~3.8 hours (sc)
AppearanceLyophilized powder for subcutaneous injection
FormulationLyophilized Powder
PubChem CID16130199
FDA UNII19OWO1T3ZE
ChEMBLCHEMBL525076

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Enfuvirtide is a thirty-six-amino-acid peptide derived from the HR2 region of the HIV-1 envelope glycoprotein gp41. During viral entry gp41 must fold so that its HR1 and HR2 regions pack into a six-helix bundle, and it is the energy of that collapse that pulls the viral and cell membranes together. Enfuvirtide binds the exposed HR1 groove in the transient pre-hairpin intermediate and occupies the site HR2 would use, preventing the bundle from forming and arresting fusion before the viral core enters the cell. Because it acts outside the cell on a structural rearrangement rather than on an enzyme, it retains activity against virus resistant to reverse transcriptase and protease inhibitors.

Origin

Synthetic peptide corresponding to gp41 HR2.

Targets

HIV-1 gp41

Research statistics

804 PubMed publications · 32.0% human clinical research · 40 registered trials

Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Enfuvirtide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

Regulatory and research status for Enfuvirtide
FDA statusApproved
AvailabilityPrescription-Only
WADA (sport)Permitted
Library classificationFDA-Approved

How FDA approval, compounding and research-only status differ

Benefits

Salvage HIV therapyNovel fusion-inhibitor class

Enfuvirtide side effects

The effects below are drawn from Enfuvirtide's prescribing information, which lists the full adverse-reaction data.

Side Effects

  • Injection-site reactions (very common)
  • Pneumonia signal
  • Hypersensitivity

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Enfuvirtide: frequently asked questions

What is Enfuvirtide?

FDA-approved HIV-1 fusion inhibitor (Fuzeon) for treatment-experienced patients. 90 mg subcutaneous twice daily with other antiretrovirals.

How does Enfuvirtide work?

Enfuvirtide is a thirty-six-amino-acid peptide derived from the HR2 region of the HIV-1 envelope glycoprotein gp41. During viral entry gp41 must fold so that its HR1 and HR2 regions pack into a six-helix bundle, and it is the energy of that collapse that pulls the viral and cell membranes together.

Is Enfuvirtide FDA approved?

Yes. Enfuvirtide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

What is the half-life of Enfuvirtide?

Reported half-life for Enfuvirtide is ~3.8 hours (sc). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

Is Enfuvirtide banned in sport?

Enfuvirtide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

What peptides are similar to Enfuvirtide?

Compounds most often compared with Enfuvirtide include Angiotensin II, Cetrorelix, Corticorelin and Cosyntropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Enfuvirtide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Enfuvirtide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →